Feuerstein (of TSC) just penned a dismissive blurb on AGIX even while admitting that he hasn’t followed them for two years.
The only biotech journalist I actually respected! But I haven't read him since he went behind the wall (no subscription and no interest/time) so I can't really respond. Just have to be happy that he acknowledged he hadn't paid attention in two years - which means he is probably still remembering the mess of the Montreal version of CART II vs the CCF version of CART II. Nothing similarly messy inre management has happened since.
Market Data 
Markets 
AI
